Atopic dermatitis
Immunology· 5 reviewed drugs· 12748 cited findings behind them
What the regulatory reviews cover
Regulatory review documents for several drugs for atopic dermatitis are available in this library. These include Rinvoq, indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis, where efficacy versus placebo for co-primary endpoints (IGA 0-1 and EASI-75) was statistically superior. Cibinqo is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older who are candidates for systemic therapy, with an IGA 0 or 1 responder rate (abrocitinib) of 42.8 compared to 7.9 for placebo. Dupixent is indicated for the treatment of moderate-to-severe atopic dermatitis, showing an EASI-75 improvement of 76.1. Nemluvio is indicated for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, with an IGA success (proportion) of 35.6. Ebglyss, indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years of age and older who are candidates for systemic therapy, demonstrated an IGA 0,1 with ≥2-Point reduction of 43.1 compared to 12.7 for placebo.
It is important to note that these drugs were studied in different clinical trials, and therefore, the reported figures are not directly comparable in a head-to-head manner.
The drugs — one cited result each
| Rinvoq AbbVie Inc. | Efficacy vs placebo for co-primary endpoints (IGA 0-1 and EASI-75): statistically superior ABBVIE — Rinvoq FDA Review (NDA/BLA 211675, 2024), p.84 |
| Cibinqo Pfizer Inc. | IGA 0 or 1 responder rate (abrocitinib): 42.8 Pfizer Inc. — Cibinqo FDA Review (NDA213871, ORIG 1, 2022), p.24 |
| Dupixent Regeneron Pharmaceuticals, Inc. | EASI-75 improvement: 76.1 REGENERON PHARMACEUTICALS — Dupixent FDA Review (NDA/BLA 761, p.79 |
| Nemluvio Galderma | IGA success (proportion): 35.6 Galderma — Nemluvio EMA EPAR public assessment report (EMEA/, p.109 |
| Ebglyss Almirall S A | IGA 0,1 with ≥2-Point reduction: 43.1 Almirall S A — Ebglyss EMA EPAR public assessment report (EM, p.88 |
Different drugs were studied in different trials — these figures are not head-to-head comparisons.
Explore the full evidence
Every finding behind these drugs — searchable, comparable and answerable in plain language — is in the Immunology research library →
Lists reflect the regulatory review documents in this library, not all therapies that exist. Educational reference only — not medical or investment advice.